


Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	BANCHEREAU, Jacques
Group Art Unit	1646
Examiner Name	Gyan Chandra

Sheet 1 of 2

Attorney Docket No: AGT.10006NP

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
GC	4,414,150	11/08/1983	Goeddel
	4,456,748	06/26/1984	Goeddel
	4,534,908	08/13/1985	Johnston
	4,650,674	03/17/1987	Aggarwal et al.
	4,678,751	07/07/1987	Goeddel
	4,727,138	02/23/1988	Goeddel et al.
	4,762,791	08/09/1988	Goeddel et al.
	4,828,830	05/09/1989	Wong
	4,851,219	07/25/1989	Sherwin
	4,925,793	05/15/1990	Goeddel et al.
	4,944,941	07/31/1990	Ammann
	5,082,658	01/21/1992	Palladino
	5,096,705	03/17/1992	Goeddel et al.
	5,227,158	07/13/1993	Jardieu
	5,248,499	08/28/1993	Czarniecki et al.
	5,460,811	10/24/1995	Goeddel et al.
	5,582,824	12/10/1996	Goeddel et al.
	5,595,888	01/21/1997	Gray et al.
	5,827,694	10/27/1998	Capon et al.
	5,831,023	11/03/1998	Capon et al.
↓	6,200,780	03/13/2001	Chen et al.

EXAMINER

/Gyan Chandra/

DATE CONSIDERED

12/01/2006

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) ? Applicant is to place a check mark here if English language translation is attached


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Application Number</td> <td>10/042,644</td> </tr> <tr> <td>Filing or 371(c) date</td> <td>January 8, 2002</td> </tr> <tr> <td>First Named Inventor</td> <td>BANCHEREAU, Jacques</td> </tr> <tr> <td>Group Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>Gyan Chandra</td> </tr> </table>	Application Number	10/042,644	Filing or 371(c) date	January 8, 2002	First Named Inventor	BANCHEREAU, Jacques	Group Art Unit	1646	Examiner Name	Gyan Chandra
Application Number	10/042,644										
Filing or 371(c) date	January 8, 2002										
First Named Inventor	BANCHEREAU, Jacques										
Group Art Unit	1646										
Examiner Name	Gyan Chandra										
Sheet 2 of 2	Attorney Docket No: AGT.10006NP										

GC	6,299,869	10/09/2001	Chen et al.
GC	6,299,877	10/09/2001	Chen et al.
GC	6,300,475	10/09/2001	Chen et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
GC	PANEM, Sandra, et al., "Antibodies to α -Interferon in a Patient with Systemic Lupus Erythematosus", J. Immunology, 1982, p. 1-3, vol. 129, no. 1	

EXAMINER	/Gyan Chandra/	DATE CONSIDERED	12/01/2006
----------	----------------	-----------------	------------

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/042,644
		Filing or 371(c) date	January 8, 2002
		First Named Inventor	BANCHEREAU, Jacques
		Group Art Unit	1646
		Examiner Name	Gyan Chandra
Sheet 1 of 2		Attorney Docket No: AGT.10006NP	

US PATENT DOCUMENTS			
Examiner Initial*	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document
GC	US- 2004/0067232	04/08/2004	Banchereau et al.
GC	6-291-661	09/18/2001	Graddis et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Abstract, Translation, English Language Equivalent or Search Report

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Abstract, Translation, English Language Equivalent or Search Report
GC	ANDRIANI, A., et al., "Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases", Haematologica, May-June 1996, pp. 258-260, vol. 81, no. 3.	Abstract only
	BATOCCHI, A.P., et al., "Myasthenia gravis during interferon alfa therapy", Neurology, Feb. 1995, p. 382-383, vol. 45, no. 2.	Abstract only
	BOHBOT, N.L., et al. "Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves, disease", Eur. J. Endocrinol., Mar. 2006, pp. 367-372, vol. 154, no. 3.	Abstract only
	BROD, Staley A., "Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity", Exp Biol Med, 2002, pp.981-988, vol. 227.	
	CHIEUX, V., et al., "Increased levels of antiviral MxA protein in peripheral blood of patients with chronic disease of unknown etiology", J. Med. Virol., Oct. 2001, pp. 301-308, vol. 65, no. 2.	Abstract only
	LANDAU, A., et al., "Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C", Dig. Dis. Sci., July 1999, pp. 1366-1367, vol. 44, no. 7	
	NGO, J. T., et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 491-495,	
	MASON, A.J., "Functional Analysis of the Cysteine Residues of Activan A", Molecular Endocrinology, 1994, pp. 325-332, vol. 8, no. 3.	
	HRON, J.D., et al., "Type I IFN Protects Against Murine Lupus", Journal of Immunology, 2004, pp. 2134-2142, vol. 173.	
	MURAKAMI T., et al., "Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.", J. Gastroenterol Hepatol., Sept.-Oct. 1995, p. 528-31, vol. 10, no. 5.	Abstract only

EXAMINER

/Gyan Chandra/

DATE CONSIDERED


12/01/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/042,644
Filing or 371(c) date	January 8, 2002
First Named Inventor	BANCHEREAU, Jacques
Group Art Unit	1646
Examiner Name	Gyan Chandra

Sheet 2 of 2

Attorney Docket No: AGT.10006NP

GC	OISHI, A., et al., "Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy", British Journal of Ophthalmology, 2005, pp. 1542-1543, vol. 89.	Abstract only
	RIZZI, R., et al. "Autoimmune hemolytic anemia presenting during treatment of chronic hepatitis C with interferon alpha", Apr-June 2003, p. 107-110, vol. 18, no. 2.	Abstract only
	STEWART, T.A. et al. "Induction of type I diabetes by interferon-alpha in transgenic mice", Science, June 25, 1993, p1942(5), vol. 260, no. 5116.	
	SKURKOVICH, S., et al. "A Disturbance of Interferon Synthesis with the Hyperproduction of Unusual Kinds of Interferon can trigger Autoimmune Disease and Play a pathogenic Role in AIDS: The Removal of These Interferons can be Therapeutic", Medical Hypothesis, 1994, p. 27-35, vol 42	
↓	VAN NOORT, J.M., et al., "Cell Biology of Autoimmune Diseases", International Review of Cytology 1998, pp. 127-206, vol. 178.	

EXAMINER

/Gyan Chandra/

DATE CONSIDERED

12/01/2006

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) : Applicant is to place a check mark here if English language Translation is attached